Jean‐Charles Soria
Amgen (United States) · 2,079 works · 106,005 citations · h-index 141
Top works
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- Cutaneous side-effects of kinase inhibitors and blocking antibodies
- Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.